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Hyponatraemia is an unusual complication of treatment with
highly active antiretroviral therapy (HAART) and to our
knowledge has not been reported in association with the
use of lopinavir—ritonavir in adults.1 Common to the protease
inhibitor class of antiretrovirals, the important well-recog-
nized side effects of lopinavir—ritonavir include hepatic
dysfunction, diabetes, and lipodystrophy syndrome with an
increased risk of pancreatitis.2
A 42-year old Zimbabwean man presented in July 2005
with confusion, headaches, blurring of vision, myalgia, dys-
phagia, and weight loss. He was noted to have oesophago-
pharyngeal candidiasis, bilateral uveitis, and was confused
with an expressive dysphasia. HIV serology was positive with
a CD4 count of 30 cells/mL and HIV viral load of
380 847 copies/mL. MRI of the head demonstrated symme-
trical white matter changes throughout the hemispheres in
keeping with an HIV dementia. CSF sampling showed 10
lymphocytes, 0 polymorphs, no organisms on Gram stain,
glucose 4.5 mmol/L (serum 8.9 mmol/L), and protein 0.69 g/
L. CSF PCR for herpes simplex virus, varicella-zoster virus,
enterovirus, mycobacteria, and JC virus was negative as was
cryptococcal antigen and mycobacterial culture. Toxoplasma
and syphilis serology was negative and cytomegalovirus viral
load in blood was<50 copies/mL. An EEGwas normal. He was
treated with fluconazole 200 mg once daily, co-trimoxazole
960 mg three times per week, and topical cyclopentolate
(1%), dexamethasone (0.1%), and timolol (0.25%) for uveitis.
Subsequently he was commenced on HAARTwith lamivudine
150 mg twice daily, tenofovir 245 mg once daily and lopina-
vir—ritonavir three tablets twice daily. Blood biochemistry
demonstrated a mild hepatitis with a transient rise in ALT to
184 IU/L prior to the introduction of HAART and probably
secondary to fluconazole. After five days of HAART he was
discharged with a declining ALT and plasma sodium of
133 mmol/L having been within the normal range (135—
145 mmol/L) on admission.
Two days later he was readmitted with worsening confu-
sion. He was clinically euvolemic and had a Glasgow coma
score (GCS) of 14/15. Investigations showed that cranial
imaging was unchanged but there was marked derangementin electrolytes with a serum sodium of 111 mmol/L, potas-
sium 4.8 mmol/L, urea 5.4 mmol/L, and creatinine 80 mmol/
L. Urine analysis was negative for protein, blood, nitrites,
and leukocytes. During the first five days of admission, the
paired urine and plasma osmolality ranged between 330 and
732 mOsm/kg and between 239 and 255 mOsm/kg, respec-
tively. The patient had a raised urine sodium of 76 mmol/L.
The low plasma osmolality, raised urine osmolality, and raised
urine sodium indicated a syndrome of inappropriate secre-
tion of antidiuretic hormone (SIADH). Repeat CSF sampling
was acellular, glucose 2.3 mmol/L (serum glucose 4.9 mmol/
L), and protein 0.34 mmol/L. He was treated for SIADH by
fluid restriction and HAARTwas discontinued since temporally
this was the most likely cause. Investigations to identify an
alternative etiology were negative including thyroid func-
tion, synacthen test (serum cortisol response to intramus-
cular tetracosactide) for adrenal insufficiency, chest X-ray,
and a septic screen. EEG demonstrated intermittent bursts of
a partial seizure pattern. Anticonvulsant therapy with sodium
valproate was commenced. Over six days the serum sodium
returned to normal. HAARTwas reintroduced with lamivudine
150 mg twice daily, tenofovir 245 mg once daily, and ataza-
navir—ritonavir. Electrolytes remained normal and subse-
quently tenofovir was substituted with abacavir, since the
latter has greater CNS penetration and may be beneficial in
the setting of HIV dementia.3,4
Use of lopinavir—ritonavir is set to rise as clinical trials
suggest superior clinical efficacy, no known de novo resis-
tance in treatment-naı¨ve individuals, and a reported side-
effect profile to date that is favorable.5,6 Since the only
change in the second HAART regimen was a switch from
lopinavir to atazanavir, this report indicates that lopinavir
was the most likely cause of the abrupt drop in sodium when
using lopinavir boosted with ritonavir. Normal urine analysis
did not suggest any direct tubular damage. Drugs used in the
management of HIV-related infections are known to precipi-
tate hyponatraemia through an SIADH effect (pyrazinamide,
ethambutol),7 an amiloride-like effect on the renal tubules
(high dose trimethoprim),8 or by as yet undefined mechan-
isms (amphotericin B, pentamidine).8 HAART-associated
hyponatremia is rare and described only with zalcitabine
(Roche1 product information) and lopinavir—ritonavir in
children.1 Laboratory investigations indicate that induction
84 Letters to the Editorof SIADH by lopinavir was probably responsible for the severe
hyponatraemia in our patient.
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doi:10.1016/j.ijid.2005.11.002Figure 1 Overall antimicrobial drug susceptibility (%) of Pseu-
domonas aeruginosa isolated from pediatric infections against
tested antibiotics (WGH, Venezuela, 1997—2003).Antimicrobial resistance of Pseudomonas aeru-
ginosa in pediatric infections
Problems encountered in the management of pediatric infec-
tions include treatment failure, which often occurs as a result
of antimicrobial-resistant bacterial strains; especially among
Pseudomonas aeruginosa.1,2 For this reason antimicrobial
drug activity surveillance is necessary, especially for oppor-
tunistic and nosocomial P. aeruginosa.2
In Latin America, resistant bacteria are emerging as a real
threat in the community as well as in hospital-acquired
infections, including pediatric infections.2 We reviewed sus-
ceptibility data of isolates cultured from hospitalized pedia-
tric patients with suspected community-acquired infections
in the West General Hospital (WGH) Caracas, Venezuela
between 1997 and 2003. The WGH is a 300-bed general
community hospital serving people from west Caracas. Sam-
ples were taken before antimicrobial drug therapy was com-
menced. Samples were processed and organisms identified by
traditional methods. In vitro antimicrobial susceptibility of
the isolates was assessed by an agar disk diffusion method
using Mueller—Hinton agar as recommended by the Clinical
and Laboratory Standards Institute (formerly NCCLS). Anti-
pseudomonal third generation cephalosporins and carbape-
nems are freely prescribed in hospitalized patients but
previous antimicrobial drug exposure in this patient series
was not measured; there were no chronic conditions
reported.
During this seven-year period, P. aeruginosa accounted
for 137 (4%) of 3425 bacterial isolates from children: 49%
from otorrhinolaryngological (ORL) infections, 18% urinary
tract infections, 7% skin, and 7% gastrointestinal tract,
among others. Overall susceptibility rates are shown in
Figure 1. Better antimicrobial activity was observed withciprofloxacin, meropenem, and imipenem (<5% resistant)
than for gentamycin, piperacillin and piperacillin/tazobac-
tam (>10% resistant). For urinary isolates, we found strains
resistant to norfloxacin (13%) and gentamycin (8%), but only
intermediate resistance to aztreonam, ceftazidime, and
ciprofloxacin (8% for each). Susceptibility to imipenem,
piperacillin/tazobactam, and tobramycin was 100%. In ORL
infections, we found significant resistance to carbenicillin
(18%) and some resistance to meropenem (5%) and imipenem
(3%) but 100% susceptibility to ciprofloxacin, ofloxacin, and
piperacillin/tazobactam.
